Launch week: the AltIndex Developer API is live. 25% off all plans with code LAUNCHWEEKRead the details
$4M
Net insider buying / selling at Adagio Medical Holdings (ADGM) over the last 2 years. Updated Dec 18, 2025

Are Adagio Medical Holdings Insiders Buying or Selling?

Adagio Medical Holdings (ADGM) has had no reported insider transactions in the past 90 days. The most recent was Deborah Kaster, who bought 15,000 shares at $1.20 on December 16, 2025.

Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the ADGM AI Score. For government officials trading this stock, see ADGM congressional trading.

Who’s Trading Adagio Medical Holdings Stock?

InsiderActivityTradesLast Trade
JOSEPH EDELMAN Bought $3.8M 2 Oct 20, 2025
Todd Usen Bought $230,000 1 Dec 12, 2025
Deborah Kaster Bought $18,000 1 Dec 16, 2025

Recent Adagio Medical Holdings Insider Transactions

Insider Transaction Date Type Shares Price Value
Deborah KasterDec 16, 2025Buy15,000$1.2$18,000
Todd UsenDec 12, 2025Buy207,315$1.09$230,000
JOSEPH EDELMANOct 20, 2025Buy2,190,496$1.6$3.5M
JOSEPH EDELMANOct 20, 2025Buy1,344,999$0.18$250,000

Frequently Asked Questions: Adagio Medical Holdings Insider Trading

Adagio Medical Holdings insiders have not reported any transactions in the past 90 days.

Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.

EDELMAN JOSEPH has bought the most ADGM stock in the last 2 years, with a total value of $3.8M.

According to our estimates, the total value of insider transactions for Adagio Medical Holdings in the last 2 years is positive, amounting to $4M. This indicates that insiders have predominantly bought shares, showcasing their confidence in the company's future prospects.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.